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Objectives Our aim was to determine whether myocardial fibrosis, detected by cardiovascular magnetic resonance (CMR),
represents an arrhythmogenic substrate in hypertrophic cardiomyopathy (HCM).
Background Myocardial fibrosis is identified frequently in HCM; however, the clinical significance of this finding is uncertain.
Methods We studied prevalence and frequency of tachyarrhythmias on 24-h ambulatory Holter electrocardiogram (ECG)
with regard to delayed enhancement (DE) on contrast-enhanced CMR in 177 HCM patients (age 41  16 yrs;
95% asymptomatic or mildly symptomatic).
Results Premature ventricular contractions (PVCs), couplets, and nonsustained ventricular tachycardia (NSVT) were more
common in patients with DE than those without DE (PVCs: 89% vs. 72%; couplets: 40% vs. 17%; NSVT: 28% vs.
4%; p  0.0001 to 0.007). Patients with DE also had greater numbers of PVCs (202  655 vs. 116  435),
couplets (1.9  5 vs. 1.2  10), and NSVT runs (0.4  0.8 vs. 0.06  0.4) than non-DE patients (all
p  0.0001); DE was an independent predictor of NSVT (relative risk 7.3, 95% confidence interval 2.6 to 20.4;
p  0.0001). However, extent (%) of DE was similar in patients with and without PVCs (8.2% vs. 9.1%; p 
0.93), couplets (8.5% vs. 8.4%; p  0.99), or NSVT (8.3% vs. 8.5%; p  0.35).
Conclusions In this large HCM cohort with no or only mild symptoms, myocardial fibrosis detected by CMR was associated
with greater likelihood and increased frequency of ventricular tachyarrhythmias (including NSVT) on ambulatory
Holter ECG. Therefore, contrast-enhanced CMR identifies HCM patients with increased susceptibility to ventricu-
lar tachyarrhythmias. (J Am Coll Cardiol 2008;51:1369–74) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.071fi
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fypertrophic cardiomyopathy (HCM) is the most common
ause of sudden cardiac death in the young (1–4). The
echanism of sudden death in HCM is ventricular tachy-
rrhythmia emanating from a structurally abnormal myo-
ardium, which often includes areas of fibrosis (5–10).
yocardial scars create a potentially arrhythmogenic sub-
trate and increase susceptibility to ventricular tachycardia/
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oston, Massachusetts; and the Hypertrophic Cardiomyopathy Center, Division of
ardiology, Tufts-New England Medical Center, Boston, Massachusetts. Dr.
dabag is supported in part by the Veterans Administration Clinical Science
esearch and Development Service (grant no. 04S-CRCOE 001), Washington, DC.p
Manuscript received August 2, 2007; revised manuscript received November 2,
007, accepted November 26, 2007.brillation (11,12). Indeed, gross macroscopic scarring is
requently present on post-mortem examination in HCM
atients who have died suddenly, suggesting a possible
ausal association between fibrosis and sudden death in this
isease (8–10).
See page 1375
Cardiovascular magnetic resonance (CMR) with delayed
nhancement (DE) imaging after gadolinium infusion, has
he capability of identifying myocardial fibrosis in vivo in
atients with structural heart disease (13–15). In both
schemic and dilated cardiomyopathy, the presence of DE is
n independent predictor of cardiovascular mortality, in-
luding sudden cardiac death (16–19). Although DE is
ound commonly on contrast-enhanced CMR in HCM
atients (20–22), currently there is no direct evidence that
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CMR and Arrhythmias in HCM April 8, 2008:1369–74this finding is associated with
arrhythmias, particularly nonsus-
tained ventricular tachycardia
(NSVT), an established risk fac-
tor for sudden death in HCM
(23,24). Therefore, the objective
of the present study was to assess
the relationship between DE and
ventricular and supraventricular
tachyarrhythmias evident on
24-h ambulatory Holter electro-
cardiogram (ECG) in a large co-
hort of HCM patients.
Methods
Study patients. From April 2003
to January 2007, 204 HCM pa-
tients were evaluated with contrast-
enhanced CMR and 24-h ambu-
latory Holter ECG in the HCM
centers of the Minneapolis Heart
nstitute Foundation and Tufts-New England Medical
enter (Boston). Of the 204 patients, 27 were excluded on
he basis of more than a 10-month time period between
MR and the Holter ECG. The final study population
ncluded 177 HCM patients. Median interval between the
studies was 1 month (3 months in 81%, 6 months in
8%).
Diagnosis of HCM was based on the demonstration of a
ypertrophied left ventricle (LV; wall thickness 13 mm in
dult patients or the equivalent wall thickness relative to
ody surface area in children) associated with a nondilated
V in the absence of another cardiac or systemic disease that
ould produce the magnitude of hypertrophy evident (25).
MR. The CMR (Philips Gyroscan ACS-NT 1.5T, Best,
etherlands; or Siemens Sonata 1.5-T, Erlangen, Ger-
any) was performed using steady-state free-precession
reath-hold cines in 3 long-axis planes and contiguous
0-mm short-axis slices (no gap) from the atrioventricular
ing to the apex. The DE images were acquired 15 min after
he intravenous administration of 0.2 mmol/kg gadolinium-
TPA (Magnevist, Schering, Berlin, Germany) with a
reath-hold 2-dimensional segmented inversion-recovery
equence (TI 240 to 300 ms), acquired in the same orien-
ation as the cine images.
Ventricular volumes, function, mass, and ejection fraction
ere measured for the LV using standard techniques (26),
nd analyzed with a commercial workstation (Qmass MR
ersion 6 1.6, Medis Medical Imaging Systems, the Neth-
rlands). The LV mass index (g/m2) was calculated by
ividing myocardial mass by body surface area. Maximal LV
all thickness was taken as the greatest dimension deter-
ined automatically by the Mass software at any site within
Abbreviations
and Acronyms
CMR  cardiovascular
magnetic resonance
DE  delayed enhancement
ECG  electrocardiogram
HCM  hypertrophic
cardiomyopathy
ICD  implantable
cardioverter-defibrillator
LV  left
ventricular/ventricle
NSVT  nonsustained
ventricular tachycardia
PVC  premature
ventricular contraction
ROC  receiver-operating
characteristic
SVT  supraventricular
tachycardiahe LV wall. 1To assess DE, all short-axis slices from base to apex were
nspected visually to identify areas of normal (completely
ulled) myocardium. Mean signal intensity (and standard
eviation [SD]) was derived and a threshold of 6 SD
xceeding the mean was used to define areas of DE
15,27–29). Summing the planimetered areas of DE in all
hort-axis slices yielded the total volume (g), which was also
xpressed as a proportion of total LV myocardium (% DE).
he DE analysis was performed by 1 experienced reader and
eviewed and confirmed by a second expert reader with both
f the independent observers blinded to patient identity and
linical profile. Any discrepancies in analysis between the 2
eaders was then adjudicated by a senior observer with 10
ears of CMR experience. All CMR analyses were per-
ormed by observers blinded to the clinical and the 24-h
CG data.
mbulatory Holter ECGs. Ambulatory Holter ECG re-
ordings were obtained in a standard fashion with a portable
ape recorder and modified V1 and V5 leads. Holter ECG
ecordings were scanned on a DelMar Reynolds AccuPlus
model 403) Holter Analysis System (Del Mar Reynolds
edical, Irvine, California). Arrhythmia frequency was
ormalized to 24 h in recordings which did not include a
omplete 24-h period of uninterrupted and interpretable
hythm, owing to noise or loss of signal. In patients with1
olter ECG, the study closest in time to the CMR was
nalyzed. Nonsustained ventricular tachycardia and su-
raventricular tachycardia (SVT) was defined as 3 or more
onsecutive premature complexes with a heart rate of 100
eats/min (12,24).
tatistical analyses. Data are expressed as mean  SD.
linical and demographic characteristics of the DE and
on-DE groups were compared using the Mann-Whitney
test for continuous variables, and the chi-square test for
oncontinuous variables expressed as proportions (or the
isher exact test for subgroups containing5 observations).
redictors of NSVT were assessed with logistic regression
nalysis. The multivariable regression model included DE,
ge, and maximal LV wall thickness, selected on the basis of
nivariate predictors of NSVT with p  0.1 in the study
opulation.
The ability of DE to discriminate patients who did or did
ot have NSVT on Holter ECG was assessed using the area
nder the receiver-operating characteristic (ROC) curve
c-index) with 95% confidence interval (CI). A c-index
qual to 0.5 indicates that the discrimination was no better
han random, whereas a c-index equal to 1.0 indicates
erfect discrimination. All comparisons were 2 tailed. p 
.05 was considered to be statistically significant. The SPSS
oftware version 10.0 (SPSS Inc., Chicago, Illinois) was
sed for all analyses.
esults
atient characteristics. At CMR, study patients were 41 
6 years of age (range 8 to 75 years); 129 (73%) were male
(
a
[
w
M
3
a
(
b
(
r
p
w
C
(
t
(
7
p
A
L
t
(
t
o
A
(
i
t
c
o
1
1
S
4
S
N
w
o
g
s
N
R
m
t
p
N
B
*
ram; H
1371JACC Vol. 51, No. 14, 2008 Adabag et al.
April 8, 2008:1369–74 CMR and Arrhythmias in HCMTable 1). Of the 177 patients, 168 (95%) were asymptom-
tic or mildly symptomatic (New York Heart Association
NYHA] functional classes I and II) and the other 9 (5%)
ere severely symptomatic (NYHA functional class III).
aximum LV wall thickness was 21  5 mm (range 10 to
6 mm), and 40 patients (23%) had LV outflow obstruction
t rest (gradient 30 mm Hg; range 0 to 160 mm Hg)
Table 1). A total of 102 patients (58%) were taking
eta-blockers, 39 (22%) calcium-channel blockers, and 3
2%) disopyramide. No patients were taking other antiar-
hythmic medications, including amiodarone. A similar
roportion of patients in the DE and non-DE subgroups
ere taking cardioactive medications (Table 1).
MR findings. Delayed enhancement was evident in 72
41%) of the 177 patients, occupying 8.5  8% (range 0.6%
o 37.6%) of LV myocardium. Areas of DE were transmural
75% of any segmental wall thickness) in 39 (54%) of the
2 patients and nontransmural DE in the other 33 (46%)
atients in discrete (focal), multifocal, or confluent patterns.
reas of DE were localized to the ventricular septum (n 6),
V free wall (n  17), at the right ventricular insertion into
he septum (n  10), or in a combination of these locations
n  39). Distribution of DE was subendocardial in 5 pa-
ients, midmyocardial in 8, epicardial in 6, or a combination
f these in 53.
mbulatory Holter ECG. Over 24 h of Holter ECG, 138
78%) of the 177 study patients had ventricular arrhythmias,
ncluding 136 (77%) with premature ventricular contrac-
ions (PVCs) (range 1 to 4,800, mean 189), 47 (27%) with
ouplets (range 1 to 99, mean 5.5), and 24 (14%) with runs
f NSVT. Number of NSVT runs in 24 h was 1 to 5 (mean
.4), with 3 to 52 beats in the longest burst (mean 8.4 
aseline Characteristics of the 177 HCM Patients With CMR and A
Table 1 Baseline Characteristics of the 177 HCM Patients Wit
All Patients
(n  177)
Age (yrs) 41 16
Male gender, n (%) 129 (73)
LV obstruction at rest (30 mm Hg), n (%) 40 (23)
Maximal LV thickness, mm 21 5
Extreme LV hypertrophy (30 mm), n (%) 8 (5)
NYHA functional class, n (%)
I 137 (77)
II 31 (18)
III 9 (5)
IV 0
Syncope, n (%) 36 (20)
Medications, n (%)
Beta-blocker 102 (58)
Calcium-channel blocker 39 (22)
Disopyramide 3 (2)
The p values reflect the comparison of patients with DE vs. those without DE (by CMR).
CMR  cardiovascular magnetic resonance; DE  delayed enhancement; ECG  electrocardiog0), and at ventricular rates of 132  23 beats/min. Runs ofVT were present in 40 patients (23%, range 1 to 93, mean
.7). Also, 47 patients (26%) had periods during which
T-segment depression (1 mm) was evident.
Patients with NSVT were older than those without
SVT (47 12 years vs. 39.5 17 years; p 0.04). There
as no statistically significant association between NSVT
n Holter ECG and maximal LV thickness, LV outflow
radient at rest, NYHA functional class, or a history of
yncope. There was no significant relationship between
SVT and the presence of ST-segment depression.
elation of arrhythmias to DE. Ventricular tachyarrhyth-
ias were significantly more common in patients with DE
han in those without DE (p 0.0001 to 0.007) (Fig. 1). In
articular, patients with DE had a 7-fold higher risk of
SVT than non-DE patients (relative risk 7.3, 95% CI 2.6
Figure 1 Prevalence of Arrhythmias on 24-h Holter
ECG With Respect to DE in 177 HCM Patients
DE  delayed enhancement; ECG  electrocardiogram; HCM  hypertrophic
cardiomyopathy; NSVT  nonsustained ventricular tachycardia; PVC  prema-
ture ventricular contraction; SVT  supraventricular tachycardia.
latory Holter ECG
R and Ambulatory Holter ECG
DE Status
DE Present
(n  72)
DE Absent
(n  105) p Value*
43 15 39 17 0.16
55 (76) 74 (71) 0.38
16 (22) 24 (23) 0.92
23.5 5 19.5 4 0.0001
8 (11) 0 0.001
0.31
52 (72) 85 (81)
18 (25) 13 (12)
2 (3) 7 (7)
0 0
13 (18) 23 (22) 0.53
45 (63) 57 (54) 0.31
15 (21) 24 (23) 0.73
0 3 (3) 0.27
CM  hypertrophic cardiomyopathy; LV  left ventricular; NYHA  New York Heart Association.mbu
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CMR and Arrhythmias in HCM April 8, 2008:1369–74o 20.4; p  0.0001). In multivariate analysis, after adjust-
ent for age and maximal LV thickness, DE was the sole
ndependent predictor of NSVT (p  0.0001). Area under
he ROC curve, generated to assess the capability of DE to
iscriminate patients with and without NSVT, was 0.77
95% CI 0.67 to 0.87) (Fig. 2).
Figure 2 ROC Curve to Assess Ability of DE to Discriminate
Patients With and Without NSVT on Holter ECG
Area under the curve is 0.77 (95% confidence interval 0.67 to 0.87). ROC 
receiver-operating characteristic; other abbreviations as in Figure 1.
Figure 3 Cardiovascular Magnetic Resonance Image From a 36
Relatively discrete areas of delayed enhancement (arrows), shown on long-axis (A
patient, a 12-beat run of nonsustained ventricular tachycardia was present on 24-Patients with DE also had greater numbers of PVCs,
ouplets, and NSVT runs (202  655, 1.9  5, and 0.4 
.8, respectively) than did patients without DE (116  435,
.2  10, and 0.06  0.4, respectively; p  0.0001). There
as no association between ventricular tachyarrhythmias
nd transmural distribution or location of DE. Also, occur-
ence of SVT was unassociated with DE.
Among the 72 HCM patients with evidence of DE on
MR, the percentage of LV myocardium occupied by DE
as unassociated with the occurrence of ventricular tachy-
rrhythmias (i.e., PVCs, couplets, and NSVT). Indeed, %
E on CMR was similar among patients with and without
ither PVCs (8.2% vs. 9.1%; p  0.93), couplets (8.5% vs.
.4%; p 0.99), or NSVT (8.3% vs. 8.5%; p 0.35) (Fig. 3).
iscussion
hese data show that the presence of DE (by contrast-
MR), representing areas of myocardial fibrosis, is inde-
endently associated with ventricular tachyarrhythmias on
mbulatory Holter ECG in a largely asymptomatic or
ildly symptomatic cohort of HCM patients. Indeed, DE
as associated with a 7-fold increase in the risk of NSVT
nd was the sole independent predictor of this arrhythmia.
hese findings may have implications for the risk stratifi-
ation of HCM patients, because NSVT is generally re-
arded to be an independent determinant of increased risk
f sudden death in this disease (2,3,23,24,30,31).
r-Old Hypertrophic Cardiomyopathy Patient
short-axis (B) views, and comprising 4.3% of LV myocardium. In the same
ulatory Holter electrocardiogram (C). LA  left atrium; LV  left ventricle;-Yea
) and
h amb
VS  interventricular septum.
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April 8, 2008:1369–74 CMR and Arrhythmias in HCMRisk stratification strategy in HCM (based on the current
rimary prevention risk factors) is likely incomplete, owing
argely to the heterogeneity of clinical and phenotypic
xpression and the low event rate observed in this disease
31,32). Therefore, identification of additional reproducible
isk markers is essential to achieve more precise selection of
atients for primary prevention of sudden cardiac death with
he implantable cardioverter-defibrillator (ICD) (33–36).
oon et al. (21) proposed DE as a pre-disposing factor for
isease progression and sudden death in HCM using
linical risk factors as surrogates for clinical end points (21).
eraoka et al. (37) and Dimitrow et al. (38) found DE to be
ost common in HCM patients with NSVT. However,
rospective data correlating actual sudden death events with
MR findings (i.e., DE) are not yet available. In this
egard, the present data linking DE to NSVT, and by
nference to increased sudden death risk, provide some
reliminary evidence that DE could ultimately prove to be a
ew risk marker in HCM.
In the present analysis, the prevalence and frequency of
entricular arrhythmias was unrelated to % DE, suggesting
hat the presence of DE (independent of its extent) repre-
ents a marker for increased arrhythmic risk in HCM.
lthough this lack of association between extent of DE and
usceptibility to ventricular arrhythmias may seem counter-
ntuitive (39), this observation is perhaps not unlike that
ecently reported in other forms of cardiovascular disease
17,27). For example, in patients suspected of coronary
eart disease, Kwong et al. (17) demonstrated that small
reas of DE were associated with an increased risk of cardiac
vents, including sudden death and appropriate ICD dis-
harges. Furthermore, in patients with nonischemic cardio-
yopathy, inducibility of ventricular arrhythmias during
rogrammed electrical stimulation is largely unrelated to the
xtent of DE (27). Therefore, it is likely that the propensity
f an abnormal myocardial substrate, comprising fibrosis, to
enerate ventricular arrhythmias is influenced substantially
y factors other than absolute scar size (12,40). In this
egard, the present data from a large cohort of HCM
atients support the idea that even small areas of DE may be
ufficient to promote arrhythmias.
Although our cross-sectional data suggest an association
etween DE and ventricular arrhythmias in HCM, prospec-
ively designed studies in large patient populations are
equired to definitively establish DE as causally related to
udden death risk. Therefore, at present, it is premature to
egard DE as a primary risk factor for HCM patients.
evertheless, the data presented here may be relevant to
linical decision-making and considerations for prophylactic
CD therapy in individual patients. The findings suggest
hat DE, representing an abnormal myocardial substrate,
ay have some role in increasing arrhythmic risk mediated
y NSVT. Therefore, in selected patients, it is possible that
ome weight can be given to areas of DE as an arbitrator in
eaching recommendations for prophylactic ICDs when
mbiguity remains concerning individual patient risk ofudden death after assessing the conventional risk factors
2,3,31,34). However, we wish to emphasize that it is not
ur intent to promote a strategy of ICD implantation in all
CM patients with DE (with or without NSVT). Rather,
uch ambiguous management decisions involving DE
hould be carried out with patient autonomy considerations
nd the desires of the fully informed patient contributing to
he resolution (34).
In this analysis, we defined DE by using a cutoff of 6
D above the mean signal intensity of normal myocardium.
t present, there is no general consensus on this strategy or
riterion (particularly in nonischemic cardiomyopathy), and
arlier investigators have used a number of different ap-
roaches for the identification of DE, including visual
ssessment (without threshold) (29,41) as well as 2-SD
29,41) and 6-SD thresholds (15,27–29,41). In our experi-
nce, the amount of DE quantified with the 6-SD tech-
ique most closely approximates that assessed by visual
nspection, with the cutoff of 2 SD yielding 22% greater
mounts of DE than a cutoff of 6 SD. Our decision to use
 threshold of 6 SD was based on the understanding that it
rovides the highest specificity for detection and quantifi-
ation of myocardial fibrosis (15,28,29).
onclusions
mong largely asymptomatic or mildly symptomatic pa-
ients with HCM, DE was associated with increased occur-
ence and frequency of ventricular tachyarrhythmias on
mbulatory Holter ECG monitoring. Consequently,
ontrast-enhanced CMR likely identifies areas of myocar-
ial fibrosis which represent a substrate for ventricular
achyarrhythmias in HCM and a subgroup of patients with
ncreased susceptibility to potentially life-threatening ar-
hythmias. These data support the necessity for future
ongitudinal follow-up studies to clarify whether DE should
e established as an independent risk predictor for sudden
eath in HCM.
eprint requests and correspondence: Dr. A. Selcuk Adabag,
ection of Cardiology (111 C), Veterans Affairs Medical Center,
ne Veterans Drive, Minneapolis, Minnesota 55417. E-mail:
daba001@umn.edu.
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